Literature DB >> 6480826

New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia.

T Yamamura, A Yamamoto, T Sumiyoshi, K Hiramori, Y Nishioeda, S Nambu.   

Abstract

We analyzed the heterogeneity of apo E in very low density lipoprotein from 58 hyperlipidemic subjects with or without atherosclerosis, 69 patients with ischemic heart disease, and 100 apparently healthy individuals. Apo E gene frequencies in the group of healthy individuals were comparable with those in German and American populations. The distribution of six common apo E phenotypes in the groups of hyperlipidemia and ischemic heart disease was similar to that in the healthy group. In addition to the three major isoforms of apolipoprotein E (apo E-4, E-3, and E-2) and the new one (apo E-5) which was recently found in this laboratory, we have discovered an additional series of components, which showed themselves as at least three bands on an isoelectric focusing gel in the region of E-VII through E-V, in four patients with hyperlipidemia and atherosclerosis. The new series of apo E components, named apo E-Suita, was identical with the ordinary apo E in its interaction with heparin-Sepharose gel and with anti-apo E antibody. The most basic component of apo E-Suita (E-VII) was the unsialylated form and other components (E-VI and E-V), the sialylated forms. Family studies revealed that apo E-Suita was determined by inheritance of a new apo E allele located at the same locus as the hitherto known apo E components. Apo E-5 and apo E-Suita isoproteins had isoelectric points more basic than apo E-3, the parent type, by two and four units of charge, respectively. While the apo E-Suita isoprotein had the same molecular weight as ordinary major apo E isoproteins, the molecular weight of the apo E-5 isoprotein was approximately 1,500-2,000 lower than the other apo E isoproteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The incidence of abnormal apo E components, including apo E-5 and apo E-Suita, was high among patients with hyperlipidemia and ischemic heart disease (7:127), while we could not find such components among 100 healthy individuals. Moreover, five of seven patients with the abnormal apo E had overt atherosclerotic disease. The findings suggest that these kinds of apolipoprotein mutation are closely related to the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480826      PMCID: PMC425289          DOI: 10.1172/JCI111532

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins.

Authors:  G Utermann; M Jaeschke; J Menzel
Journal:  FEBS Lett       Date:  1975-08-15       Impact factor: 4.124

2.  Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man.

Authors:  G Utermann; M Hees; A Steinmetz
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

3.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

4.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

Review 5.  Lipoprotein-polyanion-metal interactions.

Authors:  M Burstein; H R Scholnick
Journal:  Adv Lipid Res       Date:  1973

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

8.  A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay.

Authors:  M L Kashyap; B A Hynd; K Robinson
Journal:  J Lipid Res       Date:  1980-05       Impact factor: 5.922

9.  Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency.

Authors:  T Yamamura; H Sudo; K Ishikawa; A Yamamoto
Journal:  Atherosclerosis       Date:  1979-09       Impact factor: 5.162

10.  The interaction of heparin with an apoprotein of human very low density lipoprotein.

Authors:  F A Shelburne; S H Quarfordt
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

View more
  7 in total

1.  Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels.

Authors:  M Smit; P de Knijff; M Rosseneu; J Bury; E Klasen; R Frants; L Havekes
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

2.  Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

Authors:  M R Wardell; S O Brennan; E D Janus; R Fraser; R W Carrell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

3.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

4.  Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.

Authors:  L Havekes; E de Wit; J G Leuven; E Klasen; G Utermann; W Weber; U Beisiegel
Journal:  Hum Genet       Date:  1986-06       Impact factor: 4.132

5.  The earlier the better: Alzheimer's prevention, early detection, and the quest for pharmacological interventions.

Authors:  Annette Leibing
Journal:  Cult Med Psychiatry       Date:  2014-06

Review 6.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

7.  Meta-analysis of the association between Apolipoprotein E polymorphism and risks of myocardial infarction.

Authors:  Aiyu Shao; Jikang Shi; Zhuoshuai Liang; Lingfeng Pan; Wenfei Zhu; Sainan Liu; Jiayi Xu; Yanbo Guo; Yi Cheng; Yichun Qiao
Journal:  BMC Cardiovasc Disord       Date:  2022-03-24       Impact factor: 2.174

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.